

KERN HEALTH SYSTEMS

Pharmacy and Therapeutics Committee

AGENDA

Hodel's Restaurant, 5917 Knudsen Drive (Hwy 99 and Olive Drive)
Bakersfield, Ca. 93308

Agenda for March 16, 2005 at 6:30 PM

The Agenda is divided into three sections:

CORRESPONDENCE AND CONSENT CALENDAR: These matters include routine non-policy financial and administrative actions, may include correspondence, and are usually approved by a single majority vote. Any Committee Member may remove an item from the correspondence and consent calendar.

REGULAR CALENDAR: These items include significant financial, administrative and policy matters.

CLOSED SESSION: These items include contracting, peer review, personnel and litigation matters and other issues to be discussed by Committee members only, with report to the public on any action taken.

REGULAR AGENDA

CORRESPONDENCE AND CONSENT CALENDAR

1. Board of Directors Meeting – All items from the November 17, 2004 P & T Committee were approved.
2. Fioricet™ butabarbital, caffeine, & acetaminophen

REGULAR CALENDAR

I. PUBLIC COMMENT

This portion of the meeting is reserved for persons to address the Committee on any matter not on this agenda but under the jurisdiction of the Committee. They may ask a question for clarification, make a referral to staff for factual information or request staff to report back to the Committee at a later meeting.

Also, the Committee may take action to direct the staff to place a matter of business on a future agenda.

SPEAKERS ARE LIMITED TO TWO MINUTES. PLEASE STATE YOUR NAME BEFORE MAKING YOUR PRESENTATION. THANK YOU!

II. Action Items

Formulary Additions/Changes - Discussion and Possible Action Regarding

- A. **Update** –
 - 1. Policies: Sample, trial period
 - 2. High cost/injectable/non-retail formulary
 - 3. DUR
 - 4. Generics
- B. **COX-2 alternative--** Wait on FDA results.
- C. **Schedule II Criteria** evaluate class utilization.
- D. **Otic—**
 - 1. ciprofloxacin/dexamethasone] (Ciprodex™)
 - 2. generics
- E. **Alprazolam** (Xanax™) utilization review
- F. **Atorvastatin** (Lipitor™) dosing review
- G. **Anticonvulsants** dosing/utilization review

**III. ADJOURN TO
CLOSED SESSION**

- 1. Closed Session Regarding Provider Rates and Contracts (California Welfare and Institutions Code Section 14087.38(m))
 - a. Closed session to consider and take action of matters pertaining to contracts, and contract negotiations with providers of health care services concerning all matters related to rate of payment.
 - (1) Closed Session Regarding Peer Review (California and Welfare Institutions Code Section (14087.38(n))
 - (2) Closed Session to discuss and discharge its responsibility to evaluate and improve the quality of care rendered by health facilities and health practitioners.

Tentative next regular meeting June 22, 2005

PLEASE NOTE: Anyone wishing information on the Kern Health Systems Pharmacy & Therapeutics Committee Agendas should contact Bruce Wearda, R.Ph., Corporate Pharmacist, at Kern Health Systems either by telephone at (661)664-5100 or in writing at the following address:

Kern Health Systems
9700 Stockdale Hwy
Bakersfield, CA 93311

Such requests must be received no later than 5:00 p.m. ten (10) calendared days prior to the next regularly scheduled Committee Meeting.